Lexeo Therapeutics (LXEO)

$10.35

-0.47

(-4.34%)

Market is closed - opens 7 PM, 11 Sep 2024

Performance

  • $10.34
    $11.17
    $10.35
    downward going graph

    0.1%

    Downside

    Day's Volatility :7.43%

    Upside

    7.34%

    downward going graph
  • $9.00
    $22.33
    $10.35
    downward going graph

    13.04%

    Downside

    52 Weeks Volatility :59.7%

    Upside

    53.65%

    downward going graph

Returns

PeriodLexeo TherapeuticsIndex (Russel 2000)
3 Months
-41.8%
0.0%
6 Months
-24.78%
0.0%
1 Year
8.46%
0.0%
3 Years
8.46%
-20.6%

Highlights

Market Capitalization
376.9M
Book Value
$4.99
Earnings Per Share (EPS)
-12.53
Wall Street Target Price
22.43
Profit Margin
0.0%
Operating Margin TTM
0.0%
Return On Assets TTM
-39.93%
Return On Equity TTM
-74.83%
Revenue TTM
0.0
Revenue Per Share TTM
0.0
Quarterly Revenue Growth YOY
0.0%
Gross Profit TTM
0.0
EBITDA
-81.5M
Diluted Eps TTM
-12.53
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-2.76
EPS Estimate Next Year
-3.02
EPS Estimate Current Quarter
-0.73
EPS Estimate Next Quarter
0.0

Analyst Recommendation

Buy
    90%Buy
    9%Hold
    0
    0%Sell
Based on 11 Wall street analysts offering stock ratings for Lexeo Therapeutics(by analysts ranked 0 to 5 stars)
Based on 11 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
10
10
10
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 116.71%

Current $10.35
Target $22.43

Technicals Summary

Sell

Neutral

Buy

Lexeo Therapeutics is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Lexeo Therapeutics
Lexeo Therapeutics
-9.02%
-24.78%
8.46%
8.46%
8.46%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
0.93%
17.32%
35.75%
73.95%
298.81%
Novo Nordisk A/s
Novo Nordisk A/s
0.96%
-0.08%
31.44%
163.47%
428.79%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
-8.66%
65.51%
21.14%
30.19%
192.84%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
0.75%
12.92%
34.78%
148.18%
173.67%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Lexeo Therapeutics
Lexeo Therapeutics
NA
NA
NA
-2.76
-0.75
-0.4
NA
4.99
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
29.93
29.93
1.54
45.05
0.17
0.08
NA
261.41
Novo Nordisk A/s
Novo Nordisk A/s
44.01
44.01
1.98
3.44
0.89
0.23
0.01
25.24
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
NA
NA
-0.49
-2.55
-15.01
0.02
NA
-0.02
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
32.84
NA
0.57
0.32
-0.03
0.13
NA
57.26
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Lexeo Therapeutics
Lexeo Therapeutics
Buy
$376.9M
8.46%
NA
0.0%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$124.7B
298.81%
29.93
32.04%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$585.3B
428.79%
44.01
34.84%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
Buy
$32.3B
192.84%
NA
-3.11%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$120.9B
173.67%
32.84
-4.74%

Company Information

Organization
Lexeo Therapeutics
Employees
69
CEO
Mr. R. Nolan Townsend
Industry
Miscellaneous

FAQs